Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies.

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders ...

Dr. James Hansen, a Yale Cancer Center researcher, and his team discovered that using an antibody related to lupus they can breach the tumor and trigger an immune response to fight it. He says ...

But promising results from a recent clinical trial suggest that broadly neutralizing antibody therapy (bNAbs) may be able to accomplish the next best thing. Data from the trial—a collaboration ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 and PD1, key targets implicated in immune evasion by tumor cells.

The latter occurs most notably in the neonate as a result of a mother with antibodies due to AITD. TPO antibodies (TPOAb) appear involved in the tissue destructive processes associated with the ...

Different types of antibodies are produced by your immune system. These five antibodies help fight disease by detecting viruses, bacteria, and other pathogens (disease-causing microorganisms) and ...